BioCatalystINTELLIGENCE

BIOTECH CATALYST CALENDAR

Next Three Months
Biotech Catalysts

Know the event. Understand the evidence. Explore FDA decisions, PDUFA dates and clinical trial readouts—with treatment-group data, safety findings and original sources behind each full report.

Explore membership — $6.99/month
CURRENT SIGNALS
74

tracked upcoming events

51 expected windows
Learning
Wed, Sep 92026
TYRATyra Biosciences
Dabogratinib · SURF302Dabogratinib program
Clinical data readoutPhase 2
01
Wed, Sep 92026
IRDOpus Genetics
OPGx-BEST1 · BIRD-1 Cohort 1OPGx-BEST1 program
Clinical data readoutReported
02
Tue, Sep 82026
EVMNEvommune
EVO756 · Phase 2bEVO756 program
Topline readoutReported
03
Tue, Sep 82026
PHVSPharvaris
Deucrictibant · CHAPTER-3Deucrictibant program
Topline readoutPhase 3
04
Fri, Sep 42026
NVSNovartis / Ionis
Pelacarsen · Lp(a)HORIZONPelacarsen program
Topline readoutPhase 3
05
Wed, Sep 22026
RAREUltragenyx
Apazunersen (GTX-102) · ASPIREApazunersen (GTX-102) program
Clinical data readoutReported
06
Tue, Sep 12026
ALMSAlumis
ESK-001 (envudeucitinib) · LUMUSESK-001 (envudeucitinib) program
Topline readoutReported
07
Sun, Aug 302026
TECXTectonic Therapeutic · AstraZeneca competitor readthrough
AZD5462 · LUMINARAAZD5462 program
Clinical data readoutPhase 2
08
Wed, Aug 262026
RVMDRevolution Medicines
Rasonque (daraxonrasib)Rasonque (daraxonrasib) program
FDA decisionApproval
09
Tue, Aug 252026
SYRESpyre Therapeutics
SPY072 · SKYWAY RASPY072 program
Topline readoutPhase 2
10
Mon, Aug 172026
ARGXargenx
VYVGART Hytrulo (efgartigimod) · ALKIVIAVYVGART Hytrulo (efgartigimod) program
Topline readoutReported
11
Mon, Aug 172026
EYPTEyePoint Pharmaceuticals
DURAVYU · LUGANODURAVYU program
Topline readoutPhase 3
12
Thu, Aug 62026
REPLReplimune
Tudriqev + nivolumabTudriqev + nivolumab program
FDA decisionAccelerated Approval
13
Wed, Aug 52026
CNTXContext Therapeutics
CT-95CT-95 program
Completed catalystReported
14
Wed, Jul 222026
NUVLNuvalent
Zidesamtinib (NVL-520)Zidesamtinib (NVL-520) program
FDA decisionNDA
15
Tue, Jul 72026
VERAVera Therapeutics
Trutakna (atacicept)Trutakna (atacicept) program
FDA decisionAccelerated Approval
16
Thu, Jun 112026
DNTHDianthus Therapeutics
Claseprubart · CAPTIVATEClaseprubart program
Clinical data readoutReported
17

Important notice: This website is provided solely for general information and research. It is not investment advice, investment advisory service, an offer or solicitation of securities, or a recommendation of any strategy, and it does not account for any person’s objectives, finances or risk tolerance. Coverage is selective and no representation is made that every relevant biotech catalyst is identified or included. Information may be incomplete, delayed or incorrect; catalyst dates and estimated windows are not guaranteed and may change. Independently verify company disclosures, regulatory filings and other primary sources before trading, and consult appropriately licensed legal, tax and investment professionals when needed. Securities investing may result in partial or total loss of capital. To the fullest extent permitted by applicable law, the site operator disclaims liability for losses arising from use of or reliance on this content.